No Data
No Data
Viridian Therapeutics (VRDN) Gets a Buy From Stifel Nicolaus
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di
Buy Rating Affirmed for Viridian Therapeutics Amidst Accelerated Clinical Progress and Market Expansion Potential
HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $27
HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $37 to $27.
Viridian Therapeutics Is Maintained at Outperform by Oppenheimer
Viridian Therapeutics Is Maintained at Outperform by Oppenheimer